Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670297 | 1.00 | CYP2D6 (0.45) | CYP2D6ALDH1A1BCHEMAOBTSHR | |
| SCHEMBL1282150 | 0.96 | CYP2D6 (0.46) | CYP2D6ALDH1A1BCHEMAOBTSHR | |
| SCHEMBL2670100 | 0.96 | CYP2D6 (0.46) | CYP2D6ALDH1A1BCHEMAOBTSHR | |
| SCHEMBL2670096 | 0.96 | CYP2D6 (0.46) | CYP2D6ALDH1A1BCHEMAOBTSHR | |
| SCHEMBL14367739 | 0.96 | CYP2D6 (0.46) | CYP2D6ALDH1A1BCHEMAOBTSHR | |
| SCHEMBL21480267 | 0.89 | KDM4E (0.48) | CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL21480263 | 0.89 | KDM4E (0.48) | CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL2670728 | 0.84 | KMT2A (0.43) | CYP2D6ALDH1A1BCHETSHRACHE | |
| SCHEMBL15416062 | 0.84 | CYP2D6 (0.44) | CYP2D6ALDH1A1BCHEMAOBACHE | |
| SCHEMBL7700618 | 0.83 | DRD4 (0.43) | CYP2D6ALDH1A1BCHEMAOBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-8618094-B2 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-31 | — | — | US | disclosed |
| EP-2097400-B1 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| EP-2540715-A1 | Fused substituted aminopyrrolidine derivative | Daiichi Sankyo Company, Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | CYP2D6 44/4885ALDH1A1 2730/4885BCHE 4046/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | CYP2D6 44/4885ALDH1A1 2730/4885BCHE 4046/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | CYP2D6 44/4885ALDH1A1 2730/4885BCHE 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.